Agalsidase Beta
Fabry Disease
Sanofiprotein_peptidePhase 4 / ApprovedActive
A
83/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 79/ 100
- Competitive Position
- 89/ 100
Competitive context
22 Active assets in the Fabry Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Recombinant Alpha-Galactosidase A Shire | Phase 4 | A |
Pegunigalsidase Alfa Chiesi Italia | Phase 3 | BBB |
Migalastat Amicus Therapeutics | Phase 3 | BBB |
Montelukast Sanofi | Phase 4 | BB |
Loratadine Sanofi | Phase 4 | BB |
View all 36 →
Same molecule, other indications
Agalsidase Beta is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →